Immediate Impact
57 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Non-small-cell lung cancer
2024 Standout
Works of H. Doubre being referenced
Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018
2020
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| H. Doubre | 510 | 357 | 57 | 111 | 33 | 607 | |
| Vincent Fallet | 529 | 464 | 99 | 97 | 44 | 660 | |
| Jang Ho Cho | 442 | 411 | 57 | 168 | 24 | 617 | |
| K. Park | 623 | 523 | 39 | 211 | 25 | 698 | |
| Bente Frimodt‐Moller | 529 | 509 | 39 | 155 | 24 | 734 | |
| Laura Capelli | 391 | 338 | 100 | 148 | 31 | 597 | |
| Chia‐Chi Lin | 317 | 318 | 115 | 183 | 25 | 614 | |
| N. B. Leighl | 554 | 490 | 37 | 203 | 32 | 739 | |
| Yun Fan | 399 | 393 | 67 | 202 | 43 | 632 | |
| R. Lamy | 403 | 477 | 34 | 123 | 31 | 605 | |
| C. Decroisette | 513 | 481 | 101 | 127 | 48 | 688 |
All Works
Loading papers...